Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Research from University of Colorado in breast cancer provides new insights
April 9th, 2009
"Taxanes are tubulin-targeting agents that are highly active in the treatment of breast cancer. The lack of cross-resistance and limited overlapping toxicities of taxanes with other agents, such as anthracycline, made it possible to incorporate them in the adjuvant treatment of early breast cancer," researchers in the United States report. "When used alone or in combination with other cytotoxic agents, taxanes significantly improved response rate, time to progression, disease-free and in some trials over-all survival in patients with advanced or metastatic breast cancer. Mature data are now emerging from the early randomized clinical trials that consistently demonstrate...
Source: Women's Health Weekly (2009-04-09)
|
